AMR genotyping panels market seen reaching $2.81 billion by 2030

The market for antimicrobial resistance genotyping panels is projected to rise from $1.45 billion in 2025 to $2.81 billion by 2030, driven by growing resistant infections, faster molecular diagnostics and tighter resistance monitoring. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Antimicrobial resistance genotyping panels help clinicians identify resistance genes faster, which can support more targeted treatment decisions. - The market’s growth reflects rising pressure on healthcare systems from resistant infections and the need for better surveillance tools.

What happened: - The Business Research Company released a market report on antimicrobial resistance (AMR) genotyping panels on Oct. 30, 2026. - The report projects the global AMR genotyping panels market will grow from $1.45 billion in 2025 to $1.66 billion in 2026. - The report forecasts the market will reach $2.81 billion by 2030. - The report links the market’s 2025-2026 growth to a 14.4% compound annual growth rate. - The report says the 2026-2030 period is expected to carry a 14.1% CAGR. - Download a free sample of the market report. - View the full market report.

The details: - AMR genotyping panels are molecular diagnostic devices that detect and analyze resistance genes in bacteria and other pathogens. - These panels can screen for multiple resistance markers at the same time. - Faster, more accurate resistance detection can help guide targeted treatment and improve patient outcomes. - The report says market growth is being driven by the rising occurrence of antimicrobial resistance, more hospital-acquired infections, better molecular diagnostic technologies, greater awareness of resistance surveillance and the availability of advanced genotyping solutions. - The report says future growth will be fueled by more investment in infectious disease diagnostics, rising demand for rapid point-of-care testing, expansion of genomic epidemiology programs, deeper use of AMR data analytics and stronger regulation around resistance monitoring. - The report highlights multiplex resistance detection panels, rapid molecular diagnostics, genomic surveillance tools, hospital-based testing and early resistance detection as major trends. - The CDC reports more than 2.8 million antimicrobial-resistant infections occur annually in the U.S.

Between the lines: - The report frames AMR genotyping panels as part of a broader shift toward faster, data-rich diagnostics in infectious disease care. - The strongest demand drivers point to both clinical urgency and public-health surveillance needs, which could keep the market expanding even as testing becomes more specialized. - North America’s lead in 2025 suggests the region’s mature healthcare infrastructure and regulatory environment are helping adoption.

What's next: - The report expects Asia-Pacific to be the fastest-growing regional market over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company also says the report package includes key technologies and future trend analysis.